Relative 11C-PiB delivery as a proxy of relative CBF: Quantitative evaluation using single-session 15o-water and 11C-PiB PET

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1199-1205

  Chen, Yin J ^a   Rosario, Bedda L ^a   Mowrey, Wenzhu ^a   Laymon, Charles M ^a   Lu, Xueling ^a   Lopez, Oscar L ^a   Klunk, William E ^a   Lopresti, Brian J ^a   Mathis, Chester A ^a   Price, Julie C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Blood flow; Kinetic modeling; PiB PET

Indexed keywords

AMYLOID BETA PROTEIN; OXYGEN 15; PITTSBURGH COMPOUND B; BENZOTHIAZOLE DERIVATIVE; CARBON; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; OXYGEN; RADIOPHARMACEUTICAL AGENT; WATER;

ADULT; AGE; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; EDUCATIONAL STATUS; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PARIETAL CORTEX; PET SCANNER; PONS; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSORIMOTOR CORTEX; TEMPORAL CORTEX; THALAMUS; TISSUE DISTRIBUTION; VENTRAL STRIATUM; WHITE MATTER; AGED; BRAIN; BRAIN CIRCULATION; CHEMISTRY; DRUG DELIVERY SYSTEM; IMAGE PROCESSING; KINETICS; MIDDLE AGED; NEUROIMAGING; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; BENZOTHIAZOLES; BLOOD-BRAIN BARRIER; BRAIN; CARBON ISOTOPES; CEREBROVASCULAR CIRCULATION; COHORT STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; MALE; MIDDLE AGED; NEUROIMAGING; OXYGEN ISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; WATER;

EID: 84938892373     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.152405     Document Type: Article

References (38)

1. Cohen AD, Klunk WE. Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis. 2014;72:117-122.
2. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319.
3. Wolk DA, Klunk W. Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep. 2009;9:345-352.
4. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181-192.
5. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557-568.
6. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
7. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106:6820-6825.
8. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65: 1509-1517.
9. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-2844.
10. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
11. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
12. 11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:1629-1638.
13. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547.
14. 11C]PIB studies. Neuroimage. 2008;42:76-86.
15. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-1972.
16. Logan J, Alexoff D, Fowler JS. The use of alternative forms of graphical analysis to balance bias and precision in PET images. J Cereb Blood Flow Metab. 2011;31:535-546.
17. McNamee RL, Yee SH, Price JC, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med. 2009; 50:348-355.
18. 11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage. 2007;36:298-312.
19. 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393-400.
20. 11C-PiB: methodologic considerations. J Nucl Med. 2013;54: 1570-1576.
21. 15O PET studies in baboons: before and after amphetamine. J Nucl Med. 2002;43:1090-1100.
22. Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the inter-commissural line for stereotactic localization of functional brain images. J Nucl Med. 1993;34:322-329.
23. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 1993;17:536-546.
24. Rosario BL, Weissfeld LA, Laymon CM, et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage. 2011;55:933-941.
25. Marchal G, Rioux P, Petit-Taboue MC, et al. Regional cerebral oxygen consumption, blood flow, and blood volume in healthy human aging. Arch Neurol. 1992;49:1013-1020.
26. 15O. II. Implementation and validation. J Nucl Med. 1983;24:790-798.
27. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27: 1533-1539.
28. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med. 1999;40:2053-2065.
29. Meltzer CC, Zubieta JK, Links JM, Brakeman P, Stumpf MJ, Frost JJ. MR-based correction of brain PET measurements for heterogeneous gray matter radioactivity distribution. J Cereb Blood Flow Metab. 1996;16:650-658.
30. Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol. 2012;64:27-81.
31. 123I-ADAM. J Nucl Med. 2008;49:176-178.
32. 11C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. Nucl Med Biol. 2000;27:487-492.
33. 18F]FP-TZTP. J Cereb Blood Flow Metab. 2008;28:420-430.
34. Cohen AD, Mowrey W, Weissfeld LA, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207-215.
35. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096-1112.
36. Blomquist G, Engler H, Nordberg A, et al. Unidirectional influx and net accumulation of PIB. Open Neuroimag J. 2008;2:114-125.
37. Devous MD, Joshi AD, Kennedy I, et al. Employing early uptake data from F18-florbetapir scans as an estimate of regional cerebral blood flow: comparison to F18-FDG. Alzheimers Dement. 2014;10(suppl):P102.
38. Joshi A, Pontecorvo M, Navitsky MA, Kennedy IA, Mintun M, Devous MD. Measuring change in beta-amyloid burden over time using florbetapir-PET and a subcortical white matter reference region. Alzheimers Dement. 2014; 10(suppl):P902.